Outcomes of high‑dose methotrexate for CNS prophylaxis in diffuse large B‑cell lymphoma with an intermediate or high CNS‑International Prognostic Index: A single‑center retrospective cohort study.
International Prognostic Index
central nervous system
diffuse large B-cell lymphoma
high-dose methotrexate
relapse
Journal
Molecular and clinical oncology
ISSN: 2049-9469
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
22
05
2022
accepted:
22
09
2022
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
8
11
2022
Statut:
epublish
Résumé
Central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) is rare (2-5% of cases), but is a devastating complication with a poor survival rate. The administration of high-dose methotrexate (HDMTX) for CNS prophylaxis in patients with DLBCL is controversial and variable in the literature. The present study aimed to evaluate the clinical outcomes of HDMTX CNS prophylaxis in patients with intermediate and high CNS-International Prognostic Index (IPI) DLBCL using real-world data. An observational retrospective cohort study was conducted of all patients with intermediate and high CNS-IPI DLBCL treated at Princess Noorah Oncology Center (King Abdulaziz Medical City, Jeddah, Saudi Arabia) between January 2010 and December 2020. Patients were treated with HDMTX either intravenously or intrathecally, according to the physician's evaluation of the patient. Data on patient clinical characteristics, CNS relapses, risk factors and survival rates were obtained from hospital records. Data were analyzed using Student's unpaired t-test and the χ
Identifiants
pubmed: 36338604
doi: 10.3892/mco.2022.2592
pii: MCO-17-6-02592
pmc: PMC9627119
doi:
Types de publication
Journal Article
Langues
eng
Pagination
159Informations de copyright
Copyright: © Al-Mansour et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Ann Hematol. 2020 Aug;99(8):1823-1831
pubmed: 32577843
Blood. 2019 Feb 28;133(9):919-926
pubmed: 30617197
Blood Adv. 2020 Aug 11;4(15):3586-3593
pubmed: 32761231
Cancers (Basel). 2020 Aug 06;12(8):
pubmed: 32781541
Br J Haematol. 2019 Oct;187(2):185-194
pubmed: 31222719
Ann Oncol. 2017 Oct 01;28(10):2511-2516
pubmed: 28961838
Am J Hematol. 2021 May 1;96(5):617-629
pubmed: 33661537
Eur J Haematol. 2016 Aug;97(2):108-20
pubmed: 27096423
J Clin Oncol. 2009 Jan 1;27(1):114-9
pubmed: 19047289
Cancer. 2010 Sep 15;116(18):4283-90
pubmed: 20564149
Blood Cancer J. 2021 Jan 7;11(1):9
pubmed: 33414443
Int J Hematol. 2019 Jul;110(1):86-94
pubmed: 31115880
Curr Treat Options Oncol. 2018 Sep 10;19(11):52
pubmed: 30203318
Blood Cancer J. 2021 Jun 16;11(6):113
pubmed: 34135307
Ann Oncol. 2004 Jan;15(1):129-33
pubmed: 14679132
J Clin Oncol. 2011 Jul 10;29(20):2766-72
pubmed: 21646602
Blood Rev. 2012 May;26(3):97-106
pubmed: 22244544
Leuk Lymphoma. 2011 Dec;52(12):2270-5
pubmed: 21745170
Ann Hematol. 2011 Jul;90(7):809-18
pubmed: 21229246
Br J Haematol. 2020 Nov;191(4):552-557
pubmed: 33190261
J Clin Oncol. 1998 Apr;16(4):1561-7
pubmed: 9552066
Ann Oncol. 2012 Oct;23 Suppl 7:vii78-82
pubmed: 22997459
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Lancet Oncol. 2022 Sep;23(9):e416-e426
pubmed: 36055310
Ann Oncol. 2013 May;24(5):1385-92
pubmed: 23247661
Br J Cancer. 2014 Sep 9;111(6):1072-9
pubmed: 25072255
Ann Oncol. 2000 Jun;11(6):685-90
pubmed: 10942056
Ann Hematol. 2009 Sep;88(9):829-38
pubmed: 19172274
Pak J Med Sci. 2017 Nov-Dec;33(6):1454-1458
pubmed: 29492077
Eur J Cancer. 2018 Apr;93:57-68
pubmed: 29477102
Cancer Chemother Pharmacol. 2020 Jan;85(1):133-140
pubmed: 31848681
Ann Oncol. 2010 May;21(5):1046-52
pubmed: 19861575